Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-12-12

Clinical Trial Update: Lucentis for Central Retinal Vein Occlusion (CRVO) [Phase 1]

View source ↗

Summary

This document reports the completion of a Phase 1 trial evaluating Lucentis (ranibizumab) for central retinal vein occlusion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lucentis (ranibizumab)

Snippet

Sponsor: California Retina Consultants | Conditions: Central Retinal Vein Occlusion | Phase 1 | Status: COMPLETED